Search results for "Neuroendocrine carcinoma"

showing 10 items of 14 documents

Concomitant Small Cell Neuroendocrine Carcinoma of Gallbladder and Breast Cancer

2014

The neuroendocrine carcinoma is defined as a high-grade malignant neuroendocrine neoplasm arising from enterochromaffin cells, usually disposed in the mucosa of gastric and respiratory tracts. The localization in the gallbladder is rare. Knowledge of these gallbladder tumors is limited and based on isolated case reports. We describe a case of an incidental finding of small cell neuroendocrine carcinoma of the gallbladder, observed after cholecystectomy for cholelithiasis, in a 55-year-old female, who already underwent quadrantectomy and sentinel lymph-node biopsy for breast cancer. The patient underwent radiotherapy for breast cancer and six cycles of chemotherapy with cisplatin and etoposi…

Pathologymedicine.medical_specialtybusiness.industryGallbladdermedicine.medical_treatmentlcsh:SurgeryCase Reportlcsh:RD1-811Settore MED/08 - Anatomia PatologicaMalignancymedicine.diseaseRadiation therapySettore MED/18 - Chirurgia Generalemedicine.anatomical_structureBreast cancerNeuroendocrine carcinomamedicineEnterochromaffin cellPharmacology (medical)CholecystectomyNeoplastic transformationbusinessQuadrantectomy
researchProduct

Anal canal mixed adenoneuroendocrine carcinoma in a young patient misdiagnosed as anal abscess.

2021

Mixed neuroendocrine non-neuroendocrine neoplasms (MiNENs) are rare tumours of gastrointestinal tract, extremely rare in anal canal. We report a case of misdiagnosed MiNEN in a 38-year-old woman initially conservatively treated for a supposed anal fistula. In a second proctological evaluation, biopsy of the anal neoformation was performed and the histological specimen diagnosed a MiNEN. The complete staging showed a disseminate disease and the patient started a chemotherapy schedule. After 6 months, stable disease was revealed at the last imaging performed and radical surgery was offered to the patient that is actually on oncological follow-up without recurrence at 1 year.

Anal fistulaAdultmedicine.medical_specialtymedicine.diagnostic_testColorectal cancerbusiness.industryAnal CanalGeneral MedicineAnal canalmedicine.diseaseAbscessAnal Canal Mixed Adenoneuroendocrine CarcinomaCarcinoma Neuroendocrinemedicine.anatomical_structureSurgical oncologyBiopsymedicineHumansFemaleRadiologyRadical surgeryDiagnostic ErrorsNeoplasm Recurrence LocalbusinessAbscessBMJ case reports
researchProduct

Neuroendocrine Neoplasms (NENs)

2021

Neuroendocrine neoplasms (NENs) represent a rare and heterogeneous group of malignancies which can develop in many different sites of our body. They originate from the cells of the diffuse neuroendocrine system. Gastroenteropancreatic NENs were classified in four categories, including NETs G1 (WD with 20% Ki-67), and NECs (PD with >20% Ki-67) in accordance with the 2019 WHO classification (IARC WHO Classification of the digestive system tumors, on 11th July 2019). Lung NENs, in accordance with the latest WHO classification, 2015 edition, are distinguished in small cell lung cancer (SCLC), large cell neuroendocrine carcinoma (LCNEC), atypical carcinoid (AC), and typical carcinoid (TC).

Pathologymedicine.medical_specialtyHeterogeneous groupLungmedicine.anatomical_structurebusiness.industryMedicineTypical carcinoidNon small cellLarge-cell neuroendocrine carcinomaWho classificationbusinessAtypical carcinoid
researchProduct

Analysis of systemic inflammatory biomarkers in neuroendocrine carcinomas of the lung: prognostic and predictive significance of NLR, LDH, ALI, and L…

2020

Background: Lung neuroendocrine carcinoma (NEC) is characterized by aggressive clinical behavior and lack of treatment advances. We evaluate the prognostic and the predictive roles of systemic inflammatory biomarkers in patient circulating blood: neutrophil–lymphocyte ratio (NLR), lactate dehydrogenase (LDH), advanced lung cancer inflammation index (ALI), and the Lung Immune Prognostic Index (LIPI) score. Methods: A total of 120 patients with small-cell lung cancer (SCLC) ( n = 110) and large cell neuroendocrine carcinoma (LCNEC) ( n = 10) were enrolled. Overall survival (OS) was evaluated by Kaplan–Meier estimator and univariate and multivariate Cox proportional hazard analyses were perfor…

Oncologymedicine.medical_specialtyLungBlood based biomarkersbusiness.industrySettore MED/06 - Oncologia Medicasmall-cell lung cancer (SCLC)systemic inflammatory responselcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensInflammatory biomarkerslcsh:RC254-282Neuroendocrine Carcinomasmedicine.anatomical_structureOncologyInternal medicinemedicinePrognostic biomarkerNeuroendocrine carcinomaOriginal Articlebusinesspredictive biomarkerprognostic biomarkerneuroendocrine tumorPredictive biomarkerblood-based biomarker
researchProduct

"Pure" large cell neuroendocrine carcinoma of the gallbladder. Report of a case and review of the literature

2016

Primary Neuroendocrine Tumours (NETs) of the gallbladder are rare. Among all NETs of the gallbladder, large cell neuroendocrine carcinoma (LCNEC) is exceedingly rare. In most of the cases LCNECs are combined with other histological components. We reviewed clinical presentation and management of all patients with "pure" LCNEC from published literature since the first case was published in 2000, as well as one patient from our experience. Only 7 cases of "pure" LCNEC has been described in the last 15 years, our case is the eighth. The diagnosis of gallbladder NETs is rarely made preoperatively since the presentation generally consists of non-specific symptoms including upper abdominal pain, d…

medicine.medical_specialtyCarcinoma; Gallbladder; Large cell neuroendocrine carcinoma; Neuroendocrine carcinoma; Neuroendocrine tumours; SurgeryGallbladder Neuroendocrine Carcinomamedicine.medical_treatmentGallstonesAdenocarcinomaNeuroendocrine tumorsSettore MED/08 - Anatomia PatologicaDiagnosis Differential03 medical and health sciences0302 clinical medicineNeuroendocrine tumourmedicineCarcinomaHepatectomyHumansAgedIncidental Findingsbusiness.industryLarge cell neuroendocrine carcinomaGallbladderGeneral surgeryLiver NeoplasmsCarcinomaGallbladderGeneral MedicineGallstonesmedicine.diseaseCarcinoma NeuroendocrineNeuroendocrine TumorsSettore MED/18 - Chirurgia Generalemedicine.anatomical_structureCholecystectomy Laparoscopic030220 oncology & carcinogenesisNeuroendocrine carcinomaCarcinoma Large CellFemaleGallbladder Neoplasms030211 gastroenterology & hepatologySurgeryCholecystectomyRadiologyGallbladder NeoplasmDifferential diagnosisbusiness
researchProduct

FOLFIRINEC: a randomized phase II trial of mFOLFIRINOX vs platinum-etoposide for metastatic neuroendocrine carcinoma of gastroenteropancreatic or unk…

2021

Abstract Background Poorly differentiated neuroendocrine carcinomas (NEC) are rare diseases with a poor prognosis. Platinum-etoposide (PE) has been the recommended first-line treatment for decades. FOLFIRINEC (NCT04325425) is a national multicenter randomized phase II study which aims to challenge this standard regimen. Methods The primary objective is to compare the median progression-free survival (PFS) under mFOLFIRINOX versus PE. The secondary objectives are to evaluate the objective response rates (ORR), median overall survival (OS), safety and quality of life. The associated real-time translational study will establish a molecular profile for each patient enrolled. Main inclusion crit…

OncologyMaleFOLFIRINOXmedicine.medical_treatmentLeucovorinPhases of clinical researchPlatinum Compounds0302 clinical medicineAntineoplastic Combined Chemotherapy ProtocolsProspective StudiesNeoplasm MetastasisEtoposideEtoposideGastroenterologyEvaluable DiseaseProgression-Free Survival3. Good healthFOLFIRINOXOxaliplatinSurvival RateNeuroendocrine TumorsTreatment Outcome030220 oncology & carcinogenesisNeuroendocrine carcinoma030211 gastroenterology & hepatologyFemaleFluorouracilmedicine.drugAdultmedicine.medical_specialtyIrinotecanGastroenteropancreatic03 medical and health sciencesStomach NeoplasmsInternal medicineIntestinal NeoplasmsmedicineChemotherapyHumansContraindicationChemotherapyHepatologyPerformance statusbusiness.industry[SDV.MHEP.HEG]Life Sciences [q-bio]/Human health and pathology/Hépatology and Gastroenterology[SDV.MHEP.HEG] Life Sciences [q-bio]/Human health and pathology/Hépatology and GastroenterologyCarcinoma NeuroendocrinePancreatic NeoplasmsRegimenQuality of LifeNeoplasms Unknown PrimarybusinessBiomarkersDigestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
researchProduct

The association between appendicitis severity and patient age with appendiceal neoplasm histology—a population-based study

2022

Abstract Purpose Recent studies have reported alarming appendiceal tumor rates associated with complicated acute appendicitis, especially in patients presenting with a periappendicular abscess. However, the data on histology of appendiceal tumors among acute appendicitis patients is limited, especially in patient cohorts differentiating between uncomplicated and complicated acute appendicitis. We have previously reported the association of increased appendiceal tumor prevalence with complicated acute appendicitis in this population-based study. The objective of this secondary analysis was to evaluate the association of both appendicitis severity and patient age with appendiceal tumor histol…

UNCOMPLICATED ACUTE APPENDICITISAdultumpilisäketulehdusINTERVAL APPENDECTOMYANTIBIOTIC-THERAPYAdenocarcinoma3121 Internal medicineCONSERVATIVE TREATMENTNeuroendocrine tumorhistologiaMANAGEMENTAppendectomyHumansPseudomyxoma peritoneiINCREASED RISKMETAANALYSISMixed adeno-neuroendocrine carcinomapseudomyxoma peritoneiappendicitis severityappendiceal adenocarcinomaGastroenterologyneuroendokriiniset kasvaimetAppendiceal adenocarcinomaSERIESAppendicitisTUMORSAbscesskarsinoomatAppendiceal Neoplasms3121 General medicine internal medicine and other clinical medicineAcute Diseasemixed adeno-neuroendocrine carcinomaAppendicitis severityGoblet cell carcinomaneuroendocrine tumorgoblet cell carcinoma
researchProduct

Synchronous Two Distinct Neuroendocrine Lung Cancer Lesions

2015

Synchroniczne nowotwory płuc są rzadką chorobą, a prezentowany przypadek to pierwszy opublikowany opis jednoczesnego wystąpienia dwóch pierwotnych neuroendokrynnych raków płuca zlokalizowanych w jednym płacie. Przedstawiono przypadek 55-letniej pacjentki z dwoma pierwotnymi, odrębnymi neuroendokrynnymi rakami płata górnego płuca prawego. Pacjentka została przyjęta na oddział chirurgii klatki piersiowej w celu diagnostyki dwóch cieni okrągłych płuca prawego (o średnicy 11 i 19 mm) uwidocznionych na zdjęciu RTG klatki piersiowej wykonanym trzy miesiące wcześniej. Przy przyjęciu pacjentka nie prezentowała żadnych objawów związanych ze zmianami w płucu. Dalsze badania obrazowe wykazały zmiennoś…

Pulmonary and Respiratory MedicinePathologymedicine.medical_specialtyLung NeoplasmsLung biopsySmall-cell carcinomasynchronous primary lung cancerNeoplasms Multiple PrimarymedicineHumansCarcinoma Small CellLung cancerdrobnokomórkowy rak płucalarge cell neuroendocrine carcinomasmall cell carcinomaEtoposideCisplatinLungbusiness.industrywielkokomórkowy neuroendokrynny rak płucaNeoplasms Second PrimaryMiddle Agedmedicine.diseaseCarcinoma Neuroendocrinemedicine.anatomical_structureCardiothoracic surgeryFemaleProphylactic cranial irradiationTomography X-Ray Computedbusinesssynchroniczny rak płucamedicine.drugAdvances in Respiratory Medicine
researchProduct

Perioperative Chemotherapy in Poorly Differentiated Neuroendocrine Neoplasia of the Bladder: A Multicenter Analysis

2020

There is scant evidence about optimal management of poorly differentiated neuroendocrine carcinoma of the bladder (BNEC). We performed a multicenter retrospective study on BNEC patients from 13 Italian neuroendocrine-dedicated centers to analyze strategies associated with better outcomes. Mixed adeno-neuroendocrine carcinomas (MANEC) were included. We analyzed overall survival (OS) in the overall cohort, relapse-free survival (RFS) in radically operated patients and progression-free survival (PFS) in patients who received chemotherapy for metastatic disease. Fifty-one BNEC patients were included (male: 46, median age: 70 years). Overall, median OS was 16.0 months, radical tumor resection wa…

Oncologymedicine.medical_specialtymedicine.medical_treatmentNeuroendocrine Carcinoma (NEC)030232 urology & nephrologylcsh:MedicineDiseaseSmall-cell carcinomaArticle03 medical and health sciences0302 clinical medicineInternal medicineMedicinedisease-specific survivalStage (cooking)prognostic factorbladdersmall cell carcinomaChemotherapyPerformance statusbusiness.industryPoorly differentiatedlcsh:Rprognostic factorsRetrospective cohort studyGeneral Medicinemedicine.diseaseperioperative chemotherapy030220 oncology & carcinogenesisCohortbusinessbladder; disease-specific survival; neuroendocrine carcinoma (nec); perioperative chemotherapy; prognostic factors; small cell carcinomaJournal of Clinical Medicine
researchProduct

Primary small cell neuroendocrine carcinoma of the breast: The histogenetic diatribe

2013

The article entitled “Primary small cell neuroendocrine carcinoma of the breast: a report of two cases and review of the literature” by Spinelli et al. [1]. The authors stated that “the histogenesis is still unclear because the presence of neuroendocrine cells in normal breast has not been proved conclusively”. Moreover they reported two histogenetic hypotheses, the first one stating that “small cell neuroendocrine carcinoma (SCNC) is a variant of metaplastic carcinoma arising from a lobular or ductal carcinoma”, the second one claiming that “it is a distinct type of breast carcinoma different from the usual type”. We appreciate this case report and we agree with the authors on the histogen…

Pathologymedicine.medical_specialtyPrimary (chemistry)business.industrylcsh:Rlcsh:Medicineductal carcinomaSettore MED/18 - Chirurgia GeneraleBreast cancerSmall cell neuroendocrine carcinomaBreast cancer NeuroendocrineMedicinebusinesssmall cell neuroendocrine carcinoma (SCNC)
researchProduct